Innovation with Purpose, Powered by Science, Centered on Patients: Edwards' Commitment to Drive Value for the Healthcare Ecosystem

Edwards Lifesciences (NYSE:EW) will outline its patient-focused strategy and share financial guidance during its annual investor conference. Entering 2026 with momentum for sustainable differentiated growth, Edwards is uniquely positioned with leading therapies across its core structural heart innovations for patients with aortic stenosis (AS), mitral regurgitation (MR), tricuspid regurgitation (TR) and pulmonic diseases, and expanding into emerging opportunities to advance treatments for aortic regurgitation (AR) and structural heart failure.

"As we enter 2026, we are poised for sustainable growth and long-term value creation," said Bernard Zovighian, Edwards' CEO. "For the more than 20 million structural heart patients worldwide, we are continuing to bring novel and differentiated innovations and world-class evidence to transform care. In addition, we are excited to pioneer therapies for the many structural heart patient groups currently unaddressed today, such as those with asymptomatic AS and those with mitral, tricuspid or aortic regurgitation in need of a transcatheter replacement. Edwards is the only company committed to delivering first-of-its-kind innovations for all of these patients, leveraging our 65 years of leadership and valve expertise. This approach underscores our unwavering commitment to creating long-term value for patients, physicians, health systems and shareholders."

Highlights of today's conference include:

• Reaffirming our previously increased 2025 total company constant currency sales growth guidance of the high end of 9% to 10%; and EPS of $2.56 to $2.62
• Projecting 2026 constant currency sales growth of 8% - 10%; adjusted leveraged EPS of $2.80 - $2.95, including dilution from planned JenaValve acquisition, with ~100bps of operating margin expansion at the midpoint:
  • TAVR sales of $4.6 - $4.9 billion; constant currency growth of 6% - 8%
  • TMTT sales of $740 - $780 million; constant currency growth of 35% - 45%
  • Surgical sales of $1.05 - $1.13 billion; mid-single digit constant currency growth
• Advancing broad and balanced portfolio of structural heart therapies in 2026 and beyond with:
  • SAPIEN as the global TAVR benchmark enabling a new era of proactive disease management
  • Groundbreaking TMTT portfolio with PASCAL, EVOQUE and SAPIEN M3 systems
  • Surgical performance driving RESILIA innovations to transform patients' lives globally
  • New therapeutic areas including Structural Heart Failure and TAVR-AR
• Increasing contribution from our expanding structural heart portfolio in the long term; targeting ~10% average annual constant currency sales growth with EPS leverage:
  • Mid-to-high single digit TAVR growth
  • TMTT to reach $2 billion by 2030
  • Additional growth contribution from Structural Heart Failure and TAVR-AR